Day 1 :
Keynote Forum
Nira Ben-Jonathan
University of Cincinnati, USA
Keynote: Dopamine receptor type 1 (D1R) in breast Cancer: Expression, signaling and therapeutic applications
Time : 09:30 - 10:15
Biography:
Nira Ben-Jonathan published 175 manuscripts, edited one book, and contributed 12 chapters to textbooks and encyclopedias. She mentored 65 students, fellows and research scientists. She was awarded the NIH Research Career Development Award, was elected Fellow of the AAAS, and elected Chairman of the Gordon Research Conference on Prolactin. She received the Rieveschl Award for Outstanding Scientific Research, and the Edward Merker Lectureship in Translational Endocrinology. Over the years, she served as a member on numerous study sections of the NIH, DOD, and the Komen foundation, and as chairman on five NIH study sections.
Abstract:
Dopamine (DA) is a catecholamine which acts as a neurotransmitter in the brain and as a circulating hormone in the periphery. DA binds to five G-protein-coupled receptors, classified by their ability to increase cAMP (D1R and D2R) or decrease cAMP (D2R, D3R and D4R). We discovered D1R overexpression in breast cancer cell lines and tumors, thus identifying this receptor as a biomarker and a novel therapeutic target in breast cancer. Using tissue microarrays, D1R was overexpressed in 30% of 751 primary breast carcinomas, and was undetectable in normal breast tissue. D1R overexpression was associated with larger tumors, higher grades, node metastasis, and shorter patient survival. Unexpectedly, selective D1R agonists signal via the cGMP/protein kinase G (PKG) pathway. Activators of this pathway suppressed cell viability, inhibited cell invasion, increased chemosensitivity, and induced apoptosis in breast cancer cell lines. Fenoldopam, a peripheral D1R agonist which does not penetrate the brain, dramatically suppressed growth of D1R-expressing xenografts in two mouse models by increasing both apoptosis and necrosis. We also developed a fluorescent imaging method for D1R-expressing tumors and metastases in these mice. Ongoing studies are optimizing a positron emission tomography (PET) imaging for detecting D1R-expressing tumors in patients. In conclusion, D1R overexpression is associated with advanced disease and poor prognosis. Activation of the D1R/cGMP/PKG pathway induces apoptosis in vitro and causes tumor shrinkage in vivo. Fenoldopam, which is FDA-approved to treat acute renal hypertension, could be repurposed as a novel therapeutics for a sub-population of patients with D1R-expressing breast tumors who fail to respond to conventional treatments.
Keynote Forum
Yoshiaki Omura
New York Medical College, USA
Keynote: Clinical application of 8 unique beneficial effects of individually determined optimal dose of vitamin D3 for safe, effective treatment of cancer as well as prevention of possible cancer infection due to mixed infection of human Papilloma virus - type 16 (HPV-16) & intracellular single cell parasite Toxoplasma Gondii as a potential source of cancer spread
Time : 10:15-11:00
Biography:
Dr. Omura (M.D) Yokohama City University, with internship at Toyoko University Hospital, Tokyo and Sc.D. - in Pharmaco-Electrophysiology of Single Cardiac Cells, Columbia University, New York), far-reaching expertise is rooted in a strong academic background involving an unusual combination of fields including experimental physics (B.S. in Applied Physics, Waseda University, Tokyo--the founder of the SONY Corporation graduated from the same Engineering School--and three years in Graduate Experimental Physics, non-matriculated, Columbia University), medical electronics (Research Professor, Department of Electrical Engineering, Manhattan College, where he introduced the first course in Biomedical Electronics), and basic and clinical medicine (Research Fellow in Cardiovascular Surgery, and Residency at the Cancer Research Hospital, Columbia University) from both Western and Oriental perspectives (several teaching and research Professorship appointments at various universities in Japan and the U.S.).
Abstract:
Our previous study indicated that individually determined optimal dose of Vitamin D3 has following 8 unique, beneficial effects: 1) significant Anti-cancer effects without side effects; 2) marked decrease in DNA mutation which is proportional to the decrease in 8-OH-dG; 3) marked urinary excretion of Viruses, Bacteria, Fungi, single-cell parasites, & Toxic substances, including Asbestos & metals such as Hg, Pb, & Al; 4) marked increase in Acetylcholine in the brain & the rest of the body; 5) marked increase in DHEA; 6) marked decrease in β-Amyloid (1-42) in brain; 7) marked decrease in Cardiac Troponin I, and 8) anti-allergic effects. Also, our study indicated that average optimal dose of healthy adult is anywhere between 300-500 I.U. In the presence of the early stage of the malignancy, the optimal dose of Vitamin D3 increases to anywhere between 600-1200 I.U. when cancer is advanced it can go up to maximum of 3000 I. U. or even higher. Its anti-cancer effects are often far superior to the many standard cancer treatments without any side effects. One optimal dose usually lasts average of 8 hours. Therefore, optimal dose has to be taken 3 times a day in order to maintain beneficial effects of Vitamin D3. In addition, our recent study indicates that significant infection of Human Papilloma Virus - Type 16 (=HPV-16) co-exists together with intracellular, single-cell infection of Toxoplasma Gondii, high incidence of the malignancies was found in the infected areas. We also found when cancer advances, optimal dose of Vitamin D3 increases and when the cancer improves, optimal dose of Vitamin D3 also reduces. Therefore, non-invasive measurement of individualized optimal dose of Vitamin D3 become very important clinically. We also found family members living with cancer patients everyday in the same home and often talk in short distance in the same room, most of the family members are also infected to the same degree of the mixed infection as the cancer patients. At low level of infection, incidence of malignancy is also low. Use of optimal dose of Vitamin D3 also significantly lowers these mixed infections because one of the unique beneficial effects of Vitamin D3 is significant urinary excretion of microorganisms. Thus, taking optimal dose of Vitamin D3, even in advanced cancer patient not only inhibits cancer activity but also significantly reduces potential contributing factors of these infections. Also, for family members or nurses who have frequent daily contact with advanced cancer patients, it is highly advisable to take optimal dose of Vitamin D3 to prevent future cancer developments. However, our study indicates that beneficial effects of optimal dose of Vitamin D3 will be completely inhibited by taking overdose of Vitamin C originally promoted by Nobel Prize Winner Professor Linus Pauling.
Keynote Forum
Oroma Beatrice Nwanodi
Obstetrics and Gynecology Locum Tenens, USA
Keynote: Chemopreventive Nutraceuticals: What, Why, and How
Biography:
Oroma Beatrice Nwanodi graduated from Meharry Medical College of Nashville, Tennessee in the United States of America as a Medical Doctor in 2001. She specialized in Obstetrics and Gynecology at The University of Massachussets and Maimonides Medical Center. In 2016 she completed the Doctor of Health Science program at A. T. Still University, Mesa, Arizona. In 2017 she became triple-boarded in integrative medicine. She has publicly presented internationally in London, England, and Munich, Germany. She has served as a Conference Chair, Moderator, Organizing Committee Member, and editorial board member. She has over 30 peer-reviewed publications
Abstract:
Nutrigenomics drives DNA and RNA expression, affecting protein and downstream metabolites. Obesity, which contributes to 60% of cancers can result partly from the action of ingested nutrient and bioactive food-derived compounds on DNA and RNA expression. Conversely, metabolites of chemopreventive nutraceuticals can interact with physiologic mechanisms to reduce cancer incidence. Nutraceuticals range from active constituent phytochemicals, minerals and vitamins through whole functional foods. Nutraceuticals are the basis of at least 25% of pharmaceuticals. Epidemiological studies attribute whey-rich products with chemoprevention. Soy protein, soy isoflavones, and soy milk fermented with an array of microbes reduce breast cancer, estrogen receptor positive breast cancer, MCF-7, and colorectal cancer incidence. Fermented brown rice and bran reduce bladder, esophageal, hepatocellular, and tongue cancer incidence. Tea may be chemopreventive for breast, fibrosarcoma, gastric, glioblastoma, head and neck cancers, neuroblastoma, and prostate cancer. Chemopreventive nutraceuticals cannot be used without concern for dosage, mode of administration, or interactions with conventional medications. Nutraceutical diets can be tailored for the chemoprevention of numerous cancers, not limited to breast, cervical, endometrial, and ovarian cancer incidence reduction. Chemopreventive nutraceuticals diets can change over the lifespan for intergenerational benefits.